Clinical Trials Logo

Clinical Trial Summary

A multicenter, open, one-arm clinical study evaluated the efficacy and safety of Jinyouli in preventing neutropenia after chemotherapy in elderly lymphoma patients who met the criteria for admission. Chemotherapy regimen: The investigator selected according to the specific condition the corresponding standard chemotherapy regimen, the chemotherapy regimen used, FN risk ≥ 20%, or 10% < FN risk < 20% with at least one high risk factor for FN, from the first cycle of chemotherapy, 24-72 after chemotherapy hour subcutaneous injection of Jinyouli.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03870412
Study type Interventional
Source CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Contact Huiqiang Huang
Phone 13808885154
Email huanghq@sysucc.org.cn
Status Recruiting
Phase N/A
Start date February 22, 2019
Completion date August 22, 2021

See also
  Status Clinical Trial Phase
Completed NCT04259593 - Exercise for Elderly Lymphoma Patients N/A